A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Parkinsonism & Related Disorders

• Publication date

  2009-11-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.parkreldis.2009.03.002PMID 19345133
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology.

  2009cited by this paper
• Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.

  2008cited by this paper
• Progress in the pathogenesis and genetics of Parkinson's disease

  2008cited by this paper
• Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4‐phenylbutyrate, a chemical chaperone

  2007cited by this paper
• Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity

  2007cited by this paper
• Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis.

  2007cited by this paper
• Chemical Chaperones Reduce Endoplasmic Reticulum Stress and Prevent Mutant HFE Aggregate Formation*

  2007cited by this paper
• Suppressive effects of 4‐phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress

  2006cited by this paper
• Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2 Diabetes

  2006cited by this paper
• Chemical chaperones: mechanisms of action and potential use.

  2006cited by this paper
• The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation*

  2005cited by this paper
• Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice

  2005cited by this paper
• Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production.

  2005cited by this paper
• α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease

  2005cited by this paper
• Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.

  2005cited by this paper
• Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.

  2005cited by this paper
• The E46K mutation in alpha-synuclein increases amyloid fibril formation.

  2005cited by this paper
• Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease*

  2005cited by this paper
• Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy

  2004cited by this paper
• Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective.

  2004cited by this paper
• Pilot trial of phenylbutyrate in spinal muscular atrophy.

  2004cited by this paper
• Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.

  2004cited by this paper
• Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity.

  2004cited by this paper
• Aggresomes Formed by α-Synuclein and Synphilin-1 Are Cytoprotective*

  2004cited by this paper
• Hsp70 Reduces α-Synuclein Aggregation and Toxicity*

  2004cited by this paper
• Aggregation of α-synuclein in the pathogenesis of Parkinson’s disease

  2003cited by this paper
• Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.

  2003cited by this paper
• Human serum amyloid P component attenuates the bacterial lipopolysaccharide-induced increase in blood-brain barrier permeability in mice.

  2003cited by this paper
• alpha-Synuclein is phosphorylated in synucleinopathy lesions.

  2002cited by this paper
• α-Synuclein is phosphorylated in synucleinopathy lesions

  2002cited by this paper
• Selective and long-term learning impairment following neonatal hypoxic-ischemic brain insult in rats.

  2001cited by this paper
• A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.

  2001cited by this paper
• Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency.

  2000cited by this paper
• Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR.

  2000cited by this paper
• Long-term treatment of girls with ornithine transcarbamylase deficiency.

  1996cited by this paper
• Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.

  1995cited by this paper
• A simple quantitative bradykinesia test in MPTP-treated mice.

  1985cited by this paper

• The Therapeutic Potential of Gut-Microbiota-Derived Metabolite 4-Phenylbutyric Acid in Escherichia coli-Induced Colitis

  2025cites this paper
• Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson’s Disease Using In Vitro Models

  2025cites this paper
• 4-Phenylbutyric Acid Improves Gait Ability of UBAP1-Related Spastic Paraplegia Mouse Model: Therapeutic Potential for SPG80

  2025cites this paper
• An Alternative Pathway for the Synthesis of Glycerol Phenylbutyrate

  2024cites this paper
• 4‐Phenylbutyrate promoted wild‐type γ‐aminobutyric acid type A receptor trafficking, reduced endoplasmic reticulum stress, and mitigated seizures in Gabrg2+/Q390X mice associated with Dravet syndrome

  2023cites this paper
• Endoplasmic reticulum stress and its role in various neurodegenerative diseases.

  2023cites this paper
• Generation of resolving memory neutrophils through pharmacological training with 4-PBA or genetic deletion of TRAM

  2022cites this paper
• Living with the enemy: from protein-misfolding pathologies we know, to those we want to know.

  2021cites this paper
• Animal Models of Parkinson’s Disease

  2021cites this paper
• Targeting cellular stress in vitro improves osteoblast homeostasis, matrix collagen content and mineralization in two murine models of osteogenesis imperfecta.

  2021cites this paper
• A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson’s disease

  2020cites this paper
• Quantitative Phosphoproteomic Analysis in Alpha-Synuclein Transgenic Mice Reveals the Involvement of Aberrant p25/Cdk5 Signaling in Early-stage Parkinson’s Disease

  2020cites this paper
• Sodium 4-phenylbutyrate inhibits protein glycation.

  2020cites this paper
• Novel approaches to counter protein aggregation pathology in Parkinson's disease.

  2020cites this paper
• Rescue by 4-phenylbutyrate of several misfolded creatine transporter-1 variants linked to the creatine transporter deficiency syndrome.

  2019cites this paper
• Paraquat toxicity is attenuated by 4-phenylbutyrate-induced phosphorylation of ERK2 via PI3K in A549 cells.

  2018cites this paper
• In Vitro Anti-inflammatory Effects of the Phenylbutyric Acid Metabolite Phenylacetyl Glutamine.

  2018cites this paper
• Mechanism-based rescue of Munc18-1 dysfunction in varied encephalopathies by chemical chaperones

  2018cites this paper
• DJ-1, a Parkinson's disease related protein, aggregates under denaturing conditions and co-aggregates with α-synuclein through hydrophobic interaction.

  2017cites this paper
• Neuroprotective Effects of 4-phenylbutyric Acid and Its Derivatives: Possible Therapeutics for Neurodegenerative Diseases

  2017cites this paper
• The Selection of DNA Aptamers for the Prevention of Alpha-Synuclein Aggregation as a Therapeutic Tool in Parkinson's Disease

  2017cites this paper
• Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases

  2017cites this paper
• α-Synuclein-Related Synaptic Pathology: Novel Clues for Parkinson’s Disease Therapy

  2017cites this paper
• Orally administered sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice.

  2017cites this paper
• The Role of Histone Deacetylase Inhibition in the Accumulation and Stability of Disease-Related Proteins

  2017cites this paper
• Endoplasmic reticulum, oxidative stress and their complex crosstalk in neurodegeneration: proteostasis, signaling pathways and molecular chaperones

  2017cites this paper
• Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies.

  2017cites this paper
• Neuroprotective Effects of Germinated Brown Rice in Rotenone-Induced Parkinson’s-Like Disease Rats

  2016cites this paper
• Beneficial Effects of Sodium Phenylbutyrate Administration during Infection with Salmonella enterica Serovar Typhimurium

  2016cites this paper
• Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy

  2016cites this paper
• Phenylbutyric Acid: simple structure - multiple effects.

  2015influential citation
• Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.

  2015cites this paper
• Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate α-Synuclein Disrupted Gene Expression

  2015cites this paper
• Role of the unfolded protein response in the pathogenesis of Parkinson's disease.

  2015cites this paper
• Metabolism and epigenetics in the nervous system: Creating cellular fitness and resistance to neuronal death in neurological conditions via modulation of oxygen-, iron-, and 2-oxoglutarate-dependent dioxygenases.

  2015cites this paper
• Modulation of endoplasmic reticulum stress: an opportunity to prevent neurodegeneration?

  2015cites this paper
• The Effects of Prolyl Oligopeptidase Inhibition in α-Synuclein Based Mouse Models of Parkinson's Disease

  2015influential citation
• SEAP activity serves for demonstrating ER stress induction by glucolipotoxicity as well as testing ER stress inhibitory potential of therapeutic agents

  2015cites this paper
• Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases

  2015influential citation
• Evaluation of synthetic naphthalene derivatives as novel chemical chaperones that mimic 4-phenylbutyric acid.

  2015cites this paper
• The cytoskeletal linker protein, Ezrin, inhibits α-synuclein fibrillization and toxicity by a novel mechanism

  2014cites this paper
• Sodium phenylbutyrate reverses lysosomal dysfunction and decreases amyloid-β42 in an in vitro-model of inclusion-body myositis.

  2014cites this paper
• The promise and perils of HDAC inhibitors in neurodegeneration

  2014cites this paper
• Parkinson’s disease: animal models and dopaminergic cell vulnerability

  2014cites this paper
• [Pharmacological studies on neurodegenerative diseases focusing on refolding and degradation of unfolded proteins in the endoplasmic reticulum].

  2014cites this paper
• Chemical chaperone ameliorates pathological protein aggregation in plectin-deficient muscle.

  2014cites this paper
• Alpha synuclein in Parkinson's disease

  2014cites this paper
• Sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice

  2013cites this paper
• Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies

  2013cites this paper
• Endoplasmic Reticulum Stress and Parkinson's Disease: The Role of HRD1 in Averting Apoptosis in Neurodegenerative Disease

  2013cites this paper
• Animal Models of Parkinson’s Disease: A Gateway to Therapeutics?

  2013cites this paper
• Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation.

  2013cites this paper
• Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?

  2013influential citation
• An ERcentric view of Parkinson's disease.

  2013cites this paper
• 4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor.

  2013cites this paper
• Global Stress Response in a Prokaryotic Model of DJ-1-Associated Parkinsonism

  2013cites this paper
• Studies of the misprocessing mutations R1202D and E1204K in the drug and organic anion transporter, MRP1 (ABCC1) in cultured HEK cells

  2013cites this paper
• Discovery of Synthetic Methoxy-substituted 4-Phenylbutyric Acid Derivatives as Chemical Chaperones

  2013cites this paper
• Muscle Aging, Inclusion-Body Myositis and Myopathies: Askanas/Muscle Aging, Inclusion-Body Myositis and Myopathies

  2012cites this paper
• Amelioration of Glucolipotoxicity-Induced Endoplasmic Reticulum Stress by a “Chemical Chaperone” in Human THP-1 Monocytes

  2012cites this paper
• α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease.

  2012cites this paper
• Α-synuclein misfolding and Parkinson's disease.

  2012cites this paper
• In vitro amyloid aggregate forming ability of TGFBI mutants that cause corneal dystrophies.

  2012cites this paper
• From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease.

  2012cites this paper
• Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma.

  2012cites this paper
• Protective effects of 4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress.

  2012cites this paper
• Modelling of Parkinson's disease in mice.

  2011cites this paper
• Phenylbutyrate Up-regulates the DJ-1 Protein and Protects Neurons in Cell Culture and in Animal Models of Parkinson Disease*

  2011cites this paper
• Pathogenesis of Sporadic Inclusion‐Body Myositis: Role of Aging and Muscle‐Fiber Degeneration, and Accumulation of the Same Proteins as in Alzheimer and Parkinson Brains

  2011cites this paper
• Parkinson’s disease mouse models in translational research

  2011cites this paper
• Molecular Chaperones and Associated Cellular Clearance Mechanisms against Toxic Protein Conformers in Parkinson’s Disease

  2011cites this paper
• Targeting α-Synuclein-Related Synaptic Pathology: Novel Clues for Parkinson’s Disease Therapy

  2011cites this paper
• Hormesis, cellular stress response and vitagenes as critical determinants in aging and longevity.

  2011cites this paper
• Gastrointestinal , Hepatobiliary and Pancreatic Pathology Grp 78 Heterozygosity Regulates Chaperone Balance in Exocrine Pancreas with Differential Response to Cerulein-Induced Acute Pancreatitis

  2010cites this paper
• The cytosolic fate of ricin A chain in target cells

  2010cites this paper
• Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases

  2010cites this paper
• Genetic mouse models of Parkinson's disease The state of the art.

  2010cites this paper
• Phenylbutyric acid suppresses protein accumulation-mediated ER stress in retrovirus-infected astrocytes and delays onset of paralysis in infected mice.

  2010influential citation
• Cellular Stress Responses, The Hormesis Paradigm, and Vitagenes: Novel Targets for Therapeutic Intervention in Neurodegenerative Disorders

  2010cites this paper
• Sodium 4-phenylbutyrate ameliorates the effects of cataract-causing mutant gammaD-crystallin in cultured cells

  2010cites this paper
• Trimethylamine N-oxide alleviates the severe aggregation and ER stress caused by G98R αA-crystallin

  2009cites this paper